%0 Journal Article
%T A candidate identification questionnaire for  postmenopausal osteoporosis patients switched from daily or weekly bisphosphonate to once-monthly ibandronate: An open, prospective, multicenter study¡ªBONCURE study
%A Yesim Gokce Kutsal
%A Nurten Eskiyurt
%A Jale Irdesel
%A Vesile Sepici
%A Hatice Ugurlu
%A Yesim Kirazli
%A Fusun Ardic
%A Mirko Korsic
%A Tonko Vlak
%A Mane Grlickov
%A Snezana Markovic Temelkova
%A Miroslav Lazarov
%A Nada Pilipovic
%A Vera Popovic
%A Aleksandar Dimic
%A Branka Kovacev
%A Dorina Ruci
%A Argjend Tafaj
%A Elma Kucukalic-Selimovic
%A Dijana Avdic
%A Hajrija Seleskovic
%A Snjezana Pejicic
%A Bulent Butun
%A Gulseren Akyuz
%A Lale Cerrahoglu
%A Omer Faruk Sendur
%A Peyman Yalcin
%A Sema Oncel
%A Merih Saridogan
%A Tunay Sarpel
%A Mehmet Tosun
%A Kazim Senel
%A Savas Gursoy
%A Ferhan Canturk
%A Huseyin Demir
%A Blazenka Miskic
%A Dalibor Krpan
%A Franjo Skreb
%A Simeon Grazio
%A Zeljka Crncevic-Orlic
%A Fatih Ozdener
%A Hakan Oncel
%J Health
%P 30-40
%@ 1949-5005
%D 2013
%I Scientific Research Publishing
%R 10.4236/health.2013.57A2004
%X <p>
	<span style=\"font-size:10pt;font-family:Verdana;\">A candidate identification questionnaire
(CIQ) </span><span style=\"font-size:10.0pt;font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\">was tested to determine its predictive value for </span><span style=\"font-family:Verdana;\">patient-reported satisfaction in patients</span><span style=\"font-family:Verdana;\"> switched from once-weekly
or once-daily treatment with a bisphosphonate to once-monthly dosing. This was a
prospective, open-label, multicenter international study in patients with postmenopausal
osteoporosis who had been receiving once-daily or once-weekly alendronate or risendronate
for </span></span><span style=\"font-size:10pt;font-family:Verdana;\">at least 3 months. Patients completed
a CIQ, </span><span style=\"font-size:10.0pt;font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\">then commenced 150 mg monthly ibandronate for 6 </span><span style=\"font-family:Verdana;\">months. Patients completed the Osteoporosis </span><span style=\"font-family:Verdana;\">Patient Satisfaction Ques</span><span style=\"font-family:Verdana;\">tionnaire (OPSAT-Q</span><sup><span style=\"font-family:Verdana;\">TM</span></sup><span style=\"font-family:Verdana;\">)
at baseline for 6 months. Scores were converted to composite satisfaction scores
(CSS, scale 0-100). Totally 677 patients completed a CIQ, 645 were enrolled in
the treatment phase and comprised the intent-to-treat (ITT) population, and 630
completed the study. In the ITT population, 68.1% patients answered ¡°yes¡± to one
or more CIQ questions. OPSAT-Q scores increased for the convenience, quality of
life and overall sat</span></span><span style=\"font-size:10pt;font-family:Verdana;\">is</span><span style=\"font-size:10pt;font-family:Verdana;\">faction domains (p &lt; 0.001). Decreases in </span><span style=\"font-size:10.0pt;font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\">scores for the side effects
domains were significant (p &lt; 0.001) in the CIQ ¡°yes¡± group, but not for the
degree of bother (decrease in mean of 0.1 points, p = 0.50) or duration (no change,
p = 0.84) of non-gastrointestinal side effects. Of 638 patients who completed the
preference questionnaire, 93.0% of patients </span><span style=\"font-family:Verdana;\">preferred
the once-monthly dosing schedule</span><span style=\"font-family:Verdana;\"> and 563 patients (90.7%) found it more
convenient. The most common adverse events were dyspepsia (1.9%), nausea (1.1%),
and upper abdominal pain (0.9%). Patients are likely to prefer treatment with
%K Bisphosphonate
%K Compliance
%K Ibandronate
%K Postmenopausal Osteoporosis
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=34619